Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets...
Last week, the U.S. Food and Drug Administration (FDA) announced the approval of a new vaccine—Gardasil 9—that prevents infection...
As 2014 draws to a close, we look back on an exciting year during which we provided more than...
Earlier this month we witnessed another leap forward for immunotherapy when the FDA approved blinatumomab (Blincyto) for the treatment...
Adding the PI3-kinase inhibitor pictilisib to fulvestrant doubled progression-free survival for some women with advanced hormone-receptor positive breast cancer,...
After making great strides for some patients with melanoma and lung cancer, immunotherapy drugs are starting to offer hope...
SABCS co-chair and AACR President Carlos L. Arteaga, MD, shares his views on this year's symposium and what the...
Guest Post by T.J. Sharpe Originally appeared on Philly.com's Patient #1 blog
Through think tanks, special conferences, and its Pediatric Cancer Working Group, the AACR is taking steps to establish childhood...
With the 2014 midterm elections behind us and the U.S. Congress in the midst of a “lame duck” session,...
Nina Bhardwaj, MD, PhD, co-chair of the AACR's special conference "Tumor Immunology and Immunotherapy: A New Chapter," discusses what...